At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
sunitinib: observational studyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Etude Resume (Retraitement Sunitinib Rein Metastatique)
In Brief
An observational study evaluating sunitinib: observational study for Metastatic Renal Cell Carcinoma. Completed, enrolled 61 participants across 18 sites.
Detailed Summary
Retrospective and prospective study in mRCC patients treated with sutent in first line and rechallenged by Sutent in 3rd and 4th line.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Renal Cell Carcinoma
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 2013
Enrollment StartJul 2013
Primary CompletionApr 2014
TodayJul 2026
First PostedApr 9, 2013
Enrollment StartJul 1, 2013
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 13.2 years ago
Interventions
sunitinib: observational studyother
Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line